This page contains brief details about the drug , it's indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
Background and Date of Approval
Pamidronate consists of the active substance Pamidronate. It is a medication that belongs to a class of drugs called bisphosphonates. It is used to treat high calcium levels in the blood, a condition known as hypercalcemia, which can be caused by cancer or other medical conditions. This helps to increase bone density and reduce the risk of fractures in people with osteoporosis (bone weakening) or other bone conditions. It works by slowing down the breakdown of bone tissue, which helps reduce the amount of calcium released into the bloodstream. The dosage and frequency of administration will depend on the individual's medical condition and other factors such as age, weight, and overall health.
Pamidronate was first approved by the U.S. Food and Drug Administration (FDA) in 1991 for treating hypercalcemia of malignancy, a condition in which cancer cells release calcium into the bloodstream. Since then, pamidronate has also been approved for treating other conditions related to bone metabolisms, such as osteoporosis and Paget's disease of bone.
Mechanism of Action of undefined
Pamidronate belongs to a class of drugs called bisphosphonates, which inhibit the activity of osteoclasts. Osteoclasts are responsible for breaking down bone tissue, which releases calcium into the bloodstream. By inhibiting osteoclasts' activity, it helps slow down the breakdown of bone tissue and reduce the amount of calcium released into the bloodstream.
Uses of undefined
Pamidronate is a medication used to treat various bone-related conditions, including hypercalcemia, cancer-related bone diseases, osteoporosis, and Paget's disease of bone. It is also used in treatment of breast cancer metastasis (spread) to bone and osteolytic lesion of multiple myeloma (a type of bone cancer).
undefined Drug administaration and Dosage available
Pamidronate is a medication that is administered by a healthcare professional, typically in a hospital or clinic setting. The medication is given as an intravenous (IV) injection by healthcare professional. The infusion typically takes several hours. You will be closely monitored during and after the infusion to ensure the medication works effectively and to watch for any side effects. The dosage and frequency of administration will depend on the condition being treated and your circumstances. Your healthcare provider will determine the appropriate dosage and schedule for you.
Warnings, Precautions and Side Effects of undefined
Warnings
Pamidronate can potentially cause kidney problems, especially if you are dehydrated or have pre-existing kidney disease. Another important warning is the potential for osteonecrosis of the jaw, a rare but serious condition that causes jaw bone death. Osteonecrosis occur, especially if you have undergone dental procedures or have poor dental hygiene during taking this medication. It causes hypocalcemia, a condition characterized by low calcium levels in the blood. This can cause symptoms such as muscle spasms, tingling in the fingers and toes, and seizures. It can also cause foetal harm if administered during pregnancy.
Precautions
Patients receiving Pamidronate should take several precautions to ensure safe and effective treatment. First and foremost, they should inform their healthcare provider of any current medications, medical conditions, or allergies before starting treatment. This will help the healthcare provider determine if it is safe for the patient and adjust the treatment plan as needed. Pamidronate can interact with calcium supplements, decreasing both medication's absorption and effectiveness. Therefore, it is recommended to avoid taking calcium supplements within two hours before or after taking pamidronate. Women of reproductive potential should use effective contraception during treatment and four months after the last dose. Patients taking this medication should stay well hydrated when being treated with pamidronate. Drinking plenty of fluids can help prevent kidney problems associated with pamidronate. Therefore, it is important to stay well-hydrated during treatment. Patients should also seek immediate medical attention if they experience signs or symptoms of a serious infusion reaction, such as fever, chills, rash, hypotension, wheezing, or shortness of breath.
Side Effects
Like all medications, pamidronate can cause side effects. The most common side effects include fever, chills, fatigue, nausea, and vomiting. These side effects are usually mild and go away within a few days. However, in some cases, it can cause more serious side effects, such as kidney problems or jaw osteonecrosis (a condition in which bone tissue in the jaw dies). Infusion reactions are side effects that occur during or shortly after a medication infusion. Patients receiving this medication should be closely monitored by their healthcare provider for potential side effects.
Word Of Advice
It is important to follow the healthcare provider's instructions carefully when receiving treatment with Pamidronate. One of the most essential things you can do is attend all scheduled appointments. It will allow your healthcare provider to monitor your progress, check for any potential side effects, and adjust your treatment plan as needed. In addition to attending appointments, it is important to report any symptoms or side effects to your healthcare provider as soon as possible. It can help ensure that any issues are addressed promptly and effectively. Patients should avoid pregnancy while taking this drug. Maintaining a healthy lifestyle while receiving treatment is also essential. It includes eating a balanced diet, getting enough rest, and engaging in regular physical activity, as the healthcare provider recommends. Finally, being patient and staying positive throughout the treatment process is essential. Staying positive and optimistic can help you stay motivated and focused on your recovery.
Frequently Asked Question
References
- Goodman and Gilman's, The Pharmacological Basis of Therapeutics,12th edition, 2018, 1688-1693
- Hospira UK Ltd, Electronic Medicines Compendium (EMC), [Revised on 30th March 2023], [Accessed on 31st March 2023], https://www.medicines.org.uk/emc/files/pil.6455.pdf
Disclaimer
The drug information on this page is not a substitute for medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.